brexucabtagene autoleucel

Brexucabtagene autoleucel is a CD19-directed genetically modified autologous T cell immunotherapy, classified as a chimeric antigen receptor (CAR) T cell therapy. It is indicated for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL) and relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The therapy involves collecting a patient's own T cells, genetically modifying them to express a CAR targeting the CD19 antigen on B cells, and infusing them back into the patient to recognize and destroy malignant B cells. Developed by Kite Pharma, it is marketed under the brand name Tecartus. The drug carries significant risks including cytokine release syndrome and neurologic toxicities, requiring administration under a risk evaluation and mitigation strategy program[3][4][5][6].

Brand names

Tecartus

Other names

Autologous anti-CD19-transduced CD3+ cells